MedTrace Logo

the Pulmonary Safety of Antihepatitis C Treatment

NCT04122066 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2020-03-30

No results posted yet for this study

Summary

pulmonary side effects of the new regimen of antihepatitis C

Conditions

  • Hepatitis C

Interventions

DRUG

sofosbuvir \daclatsvir

study the effect of the new oral antihepatitis C drugs on the respiratory system

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Safaa Mokhtar · Assiut University

  • Nahed Makhlouf · Assiut University

  • Mostafa kamal · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04122066 on ClinicalTrials.gov